TABLE 1.
Meta‐analysis and subgroup analysis for the comparison of the studied outcomes between the studied groups
| Outcomes | No. of participants (case/control) | No. of studies | Quantitative data synthesis | Heterogeneity analysis | |||||
|---|---|---|---|---|---|---|---|---|---|
| WMD | 95% CI | Z‐value | p‐value | df (Q) | I 2% | p value | |||
| Serum chemerin levels in PCOS and no PCOS group | |||||||||
| Overall effect | 2256 (1191/1065) | 19 | 12.02 | 10.92, 13.13 | 21.26 | <.001 | 31 | 99.4 | <.001 |
| Subgroup analysis based on BMI (BMI >25 or <25) | |||||||||
| BMI >25 | 887 (512/375) | 14 | 3.98 | 3.02, 4.9 | 8.23 | <.001 | 14 | 98.5 | <.001 |
| BMI <25 | 834 (406/428) | 11 | 0.9 | 0.43, 1.38 | 3.74 | .065 | 11 | 98.1 | <.001 |
| Overall effect | 1721 (918/803) | 17 ( | 1.62 | 1.25, 1.99 | 8.51 | <.001 | 26 | 98.3 | <.001 |
| Subgroup analysis based on sample size of the studies (sample size >25 or <25) a | |||||||||
| Sample size <30 | 774 (443, 331) | 11 | 6.13 | 5.25, 7.01 | 13.63 | <.001 | 16 | 99.5 | <.001 |
| Sample size >30 | 1143 (605, 538) | 10 | 14.23 | 11.03, 17.43 | 8.71 | <.001 | 11 | 99.4 | <.001 |
| Overall effect | 1917 (1048, 869) | 19 | 4.12 | 3.59, 4.66 | 15.08 | <.001 | 28 | 99.3 | <.001 |
| Serum chemerin levels in PCOS group with BMI >25 or 30 and PCOS group with BMI <25 or 30 | |||||||||
| Overall effect | 800 (450/350) c | 13 | 3.29 | 2.73, 3.84 | 11.55 | <.001 | 12 | 97.5 | <.001 |
| Subgroup analysis based on BMI (BMI >25 or 30) | |||||||||
| BMI >30 | 247 (129/118) d | 5 | 20.16 | 17.15, 23.17 | 13.12 | <.001 | 4 | 98.8 | <.001 |
| BMI >25 | 448 (269/ 179) e | 5 | 2.59 | 2.02, 3.16 | 8.91 | <.001 | 4 | 82.7 | <.001 |
| Overall effect | 800 (450/350) | 10 | 3.2 | 2.64, 3.76 | 11.55 | <.001 | 12 | 98.1 | <.001 |
| Follicular fluid chemerin levels in PCOS and no PCOS groups | |||||||||
| Overall effect | 224 (114/110) | 4 | 41.7 | 17.89, 65.50 | 3.43 | .001 | 5 | 83.5 | .001 |
| Chemerin mRNA expression in PCOS and no PCOS groups | |||||||||
| Overall effect | 204 (104/100) | 3 | 0.38 | 0.25, 0.52 | 5.56 | <.001 | 4 | 82.8 | <.001 |
Abbreviations: 95% CI, 95% confidence intervals; BMI, body mass index; I 2, I‐squared; PCOS, polycystic ovary syndrome; WMD, weighted mean differences.
bSample size <30: Each study with sample size less than 30 in case or control group; Sample size >30: Each study with sample size more than 30 in both case and control group.
Considering sample size of the studies >25 or <25, serum chemerin levels compared between PCOS and no PCOS group as case and control group, respectively.
Serum chemerin levels compared between PCOS group with BMI >25 or 30 and PCOS group with BMI <25 or 30, as case and control group.
Serum chemerin levels compared between PCOS group with BMI >30 and PCOS group with BMI <30 as case and control group, respectively.
Serum chemerin levels compared between PCOS group with BMI >25 and PCOS group with BMI <25 as case and control group, respectively.